Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylaxis in rare coagulation disorders -- factor X deficiency.

G Auerswald1

  • 1Comprehensive Care Center for Thrombosis and Haemostasis, Klinikum Bremen-Mitte, Professor Hess Children's Hospital, Bremen, Germany. guenterauerswald@aol.com

Thrombosis Research
|April 1, 2006
PubMed
Summary

Factor X deficiency is a rare bleeding disorder. Treatment with Factor IX concentrate effectively controlled severe bleeding and surgical procedures in patients, with no serious complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The EPIC study: a lesson to learn.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.

Thrombosis and haemostasis·2014

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Factor X (FX) is a crucial vitamin K-dependent protease in blood coagulation.
  • FX deficiency is a rare inherited bleeding disorder with diverse clinical presentations.
  • Genetic mutations and polymorphisms underlie the molecular basis of FX deficiency.

Purpose of the Study:

  • To investigate the correlation between genetic mutations and clinical severity in Factor X deficiency.
  • To evaluate the management and outcomes of patients with Factor X deficiency.

Main Methods:

  • Established the Greifswald Registry of FX deficiency in 1998.
  • Monitored 102 patients, with 34 treated for severe bleeding or surgery.
  • Assessed outcomes of prophylaxis with Factor IX (FIX) concentrate (containing FX).

Related Experiment Videos

Main Results:

  • Severe bleeding episodes and surgical procedures were managed in 34 patients.
  • Seven patients received regular prophylaxis with FIX concentrate (containing FX).
  • Bleeding episodes were effectively controlled with FIX concentrate, showing no serious treatment-related complications.

Conclusions:

  • Factor IX concentrate is a safe and effective treatment for managing bleeding in Factor X deficiency.
  • Prophylaxis with FIX concentrate can prevent severe bleeding episodes in FX-deficient patients.
  • Further research into the genotype-phenotype relationship in FX deficiency is warranted.